The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality.

07:00 EST 14th January 2020 | BioPortfolio

Summary of "The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality."

: Hemophilia is a very expensive disease. Ameliorations in the management of hemophilia causes increased patient survival, more complex disease management, and augmented treatment costs. A literature search related to the cost of hemophilia was analyzed.: Clotting factor concentrates, which are the keystone of management, are costly. In fact, the yearly expenditure in the USA is 250,000 USD per adult patient. Indirect expenses also play a part to the economic load, and include lost productive capacity, uncompensated caretaker tariffs, and hemophilia-related physical handicap. Factor concentrates are responsible for more than 90% of the direct healthcare expenditures of hemophilia. In an evaluation of the cost of management with high-dose prophylaxis in previously untreated patients from childbirth to puberty, including immune tolerance induction (ITI), the average annual treatment cost (Euros per kilogram) was 4391 EUR (approximately 4865 USD), and the average ITI cost was 383,448 EUR (approximately 424,860 USD). The expected ITI recovery period in the aforementioned evaluation was 1.8 years. To reduce costs, strategies such as disease management programs and drug pricing programs have also been implemented.: Knowing the current cost of hemophilia is essential to ensure that patients are treated as efficiently as possible.


Journal Details

This article was published in the following journal.

Name: Expert review of hematology
ISSN: 1747-4094


DeepDyve research library

PubMed Articles [30295 Associated PubMed Articles listed on BioPortfolio]

Hemophilia A in Females: Considerations for Clinical Management.

Approximately 50% of female carriers of hemophilia A have factor VIII (FVIII) levels below 0.5 IU/dL and may be categorized as having mild hemophilia. Females with hemophilia may go undiagnosed for ye...

Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study.

Almost all of what is known about neurologic and cognitive development in hemophilia derives from the Hemophilia Growth and Development Study, conducted during an era when treatment regimens and comor...

Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia.

In Colombia, hemophilia is considered a high-cost disease, and hemophilia A with high-titer inhibitors may be responsible for a significant economic pressure on the Colombian health system.

Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer?

There are now over a dozen disease modifying therapies (DMTs) available to treat multiple sclerosis (MS). They vary in efficacy and safety as well as in cost. The literature on the cost effectiveness ...

Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China.

Clinical Trials [8618 Associated Clinical Trials listed on BioPortfolio]

Quality of Life in Hemophilia by Clinical Scoring System (FISH)Score

To asses quality of life in patients with hemophilia clinically.- -To avoid or minimize structural damage to goints and muscles by making patients aware of importance of rehabilitation

ATHN 7: Hemophilia Natural History Study

This is a real-world study of the safety of the treatments used for people with hemophilia. The study will follow people with hemophilia A or B from across the country for about 4 years as...

Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study

This is a multi-center, international study designed to collect clinical, genetic and quality of life information on females with hemophilia, an inherited bleeding disorder. The study is d...

A Prospective Study to Collect High-Quality Documentation of Bleeds Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A and Factor VIII (FVIII) Inhibitors Treated With Standard-of-Care Treatment

This non-interventional study will prospectively collect detailed, high-quality documentation of bleeds, HRQoL and safety outcomes in patients with hemophilia A and FVIII inhibitors treate...

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned...

Medical and Biotech [MESH] Definitions

The personal cost of acute or chronic disease. The cost to the patient may be an economic, social, or psychological cost or personal loss to self, family, or immediate community. The cost of illness may be reflected in absenteeism, productivity, response to treatment, peace of mind, QUALITY OF LIFE, etc. It differs from HEALTH CARE COSTS, meaning the societal cost of providing services related to the delivery of health care, rather than personal impact on individuals.

A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008)

Approach to improve the quality of care by selectively encouraging or discouraging the use of specific health care services, based on their potential benefit to patients' health, relative to their cost. One element is lowering beneficiary cost sharing or out-of-pocket spending to increase medication adherence.

The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.

The assignment, to each of several particular cost-centers, of an equitable proportion of the costs of activities that serve all of them. Cost-center usually refers to institutional departments or services.

Quick Search

DeepDyve research library

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Searches Linking to this Article